Mirae Asset Global Investments Co., Ltd. Immuno Gen, Inc. Transaction History

Mirae Asset Global Investments Co., Ltd.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 24, 2024	SELL	$12.46 - $29.95 $86,397 - $207,673	-6,934 Reduced 5.17%	127,205 $3.77 Million
Q3 2023 Oct 26, 2023	BUY	$14.09 - $19.87 $168,741 - $237,963	11,976 Added 9.8%	134,139 $2.13 Million
Q2 2023 Aug 10, 2023	SELL	$3.75 - $20.05 $88,691 - $474,202	-23,651 Reduced 16.22%	122,163 $2.31 Million
Q1 2023 May 04, 2023	BUY	$3.67 - $4.92 $189,687 - $254,295	51,686 Added 54.91%	145,814 $559,000
Q4 2022 Feb 09, 2023	BUY	$4.55 - $6.31 $354 - $492	78 Added 0.08%	94,128 $466,000
Q3 2022 Nov 10, 2022	BUY	$4.48 - $6.47 $122,093 - $176,326	27,253 Added 40.8%	94,050 $449,000
Q2 2022 Jul 26, 2022	BUY	$3.15 - $5.76 $210,410 - $384,750	66,797 New	66,797 $300,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.